ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
Recruiting
Phase 4
Interventional Study
Malaria
Malaria, Vivax
Plasmodium Vivax Malaria
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 606 (estimated)
- Sponsor
- Shoklo Malaria Research Unit · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
In this area of Greater Mekong Subregion (GMS), vivax malaria is the most common kind of malaria. It can stay very long in the liver, and come out later to make another episode of illness. This can happen many times even without a mosquito bite. Only 8-aminoquinoline drugs can kill the liver forms of the malaria parasite. One of these drugs is called primaquine, and it has been used all over the w…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with P. vivax mono-infection as diagnosed by Rapid Diagnostic Test
* Fever or history of fever in the previous 7 days
* Quantitative G6PD activity ≥70% of the population median i.e., ≥6.1U/gHb
* Age \> 18 years, Weight \>35 kg
* Ability to understand the study instruc…
Contacts